Calcified Tissue International

, Volume 71, Issue 2, pp 103–111

The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis

  • J.P. Brown
  • D.L. Kendler
  • M.R. McClung
  • R.D. Emkey
  • J.D. Adachi
  • M.A. Bolognese
  • Z. Li
  • A. Balske
  • R. Lindsay
Article

DOI: 10.1007/s00223-002-2011-8

Cite this article as:
Brown, J., Kendler, D., McClung, M. et al. Calcif Tissue Int (2002) 71: 103. doi:10.1007/s00223-002-2011-8

Copyright information

© Springer-Verlag New York Inc. 2002

Authors and Affiliations

  • J.P. Brown
    • 1
  • D.L. Kendler
    • 2
  • M.R. McClung
    • 3
  • R.D. Emkey
    • 4
  • J.D. Adachi
    • 5
  • M.A. Bolognese
    • 6
  • Z. Li
    • 7
  • A. Balske
    • 7
  • R. Lindsay
    • 8
  1. 1.Le Centre de recherche du CHUL, Laval University, Sainte-Foy, Québec, CanadaCanada
  2. 2.Providence Health Care Centre, Vancouver, British Columbia, CanadaCanada
  3. 3.Osteoporosis Research Center, Portland, Oregon, USAUSA
  4. 4.Reading Hospital and Medical Center, Reading, Pennsylvania, USAUSA
  5. 5.Department of Medicine, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, CanadaCanada
  6. 6.Bethesda Health Research, Bethesda, Maryland, USAUSA
  7. 7.Procter & Gamble Pharmaceuticals, Mason, Ohio, USAUSA
  8. 8.Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York, USAUSA